Gregg H. Alton
2018
In 2018, Gregg H. Alton earned a total compensation of $4.9M as Former Interim Chief Executive Officer and Chief Patient Officer at Gilead Sciences, a 6% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,210,230 |
|---|---|
| Option Awards | $1,250,078 |
| Salary | $1,005,381 |
| Stock Awards | $1,431,174 |
| Other | $10,000 |
| Total | $4,906,863 |
Alton received $1.4M in stock awards, accounting for 29% of the total pay in 2018.
Alton also received $1.2M in non-equity incentive plan, $1.3M in option awards, $1M in salary and $10K in other compensation.
Rankings
In 2018, Gregg H. Alton's compensation ranked 2,068th out of 14,244 executives tracked by ExecPay. In other words, Alton earned more than 85.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,068 out of 14,244 | 86th |
Division Manufacturing | 745 out of 5,759 | 87th |
Major group Chemicals And Allied Products | 247 out of 2,122 | 88th |
Industry group Drugs | 197 out of 1,811 | 89th |
Industry Biological Products, Except Diagnostic Substances | 42 out of 339 | 88th |
Source: SEC filing on March 24, 2020.
Alton's colleagues
We found three more compensation records of executives who worked with Gregg H. Alton at Gilead Sciences in 2018.